Trial Profile
A first in human study investigating safety, tolerability, and pharmacokinetics of SA-001 and its metabolite Rebamipide after single oral dose of SA-001 in fasted and fed state in healthy male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2017
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary) ; Rebamipide mofetil (Primary)
- Indications Dry eyes
- Focus Adverse reactions; First in man; Pharmacokinetics
- 08 Apr 2017 New trial record
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics